Organization (Industry)
INOVIO PHARMACEUTICALS, INC.
ClinicalTrials.gov lists INOVIO PHARMACEUTICALS, INC. as lead sponsor of 31 trials. It has 21 active development programs and 3 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers INOVIO PHARMACEUTICALS, INC.: 31 lead-sponsored trials and 3 legal-entity registrations.
Disease areas (37)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Uterine Cervical Neoplasms | 5 |
| Head and Neck Neoplasms | 4 |
| Hepatitis C | 4 |
| Squamous Intraepithelial Lesions | 4 |
| Carcinoma, Squamous Cell | 3 |
Showing 5 of 37 disease areas.
Trials by start year as sponsor or collaborator (17)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2023 | 1 |
| 2022 | 2 |
| 2021 | 4 |
| 2020 | 4 |
| 2019 | 4 |
| 2018 | 7 |
| 2017 | 2 |
| 2016 | 5 |
| 2015 | 3 |
| 2014 | 5 |
Showing 10 of 17 years.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (21)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| VGX 3100 | Uterine Cervical Dysplasia | Phase 3 | 3 |
| VGX 3100 | Squamous Intraepithelial Lesions | Phase 3 | 3 |
| Calcium electroporation | Squamous Intraepithelial Lesions | Phase 3 | 1 |
| Calcium electroporation | Uterine Cervical Dysplasia | Phase 3 | 1 |
| INO-4800 | COVID-19 | Phase 2/3 | 2 |
Showing 5 of 21 active programs.
Approved assets (3)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| ATEZOLIZUMAB | 1 |
| Cemiplimab | 1 |
| Temozolomide | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 38% hit target (n=16) | 53% on time (n=15) |
Journals published in (31)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 3 |
| The New England journal of medicine | 3 |
| Frontiers in immunology | 2 |
| Human vaccines & immunotherapeutics | 2 |
| Journal for immunotherapy of cancer | 2 |
Showing 5 of 31 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 96 | 49 | 2025-12-09 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 65,343 | -84,945,901 | 54,206,874 |
| 2024 | 217,756 | -107,254,126 | 75,620,340 |
| 2023 | 832,010 | -135,117,352 | 86,676,563 |
| 2022 | 10,262,268 | -279,818,065 | 187,650,503 |
| 2021 | 1,774,758 | -303,658,710 | 249,240,324 |
| 2020 | 7,411,220 | -166,411,157 | 94,245,436 |
| 2019 | 4,111,930 | -119,359,219 | 88,017,319 |
| 2018 | 30,481,897 | -96,967,830 | 95,257,876 |
| 2017 | 42,220,086 | -88,205,772 | 98,572,618 |
| 2016 | 35,368,361 | -73,740,339 | 88,712,035 |
Showing 10 of 11 fiscal years.
Financing and grant events (42)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-07-29 | Public offering | not disclosed | Sec extracted |
| 2026-04-02 | Public offering | not disclosed | Sec extracted |
| 2026-04-01 | ATM offering | 3,200,000 | Sec extracted |
| 2026-01-27 | Other financing | not disclosed | Edgar offerings |
| 2026-01-27 | Other financing | not disclosed | Sec extracted |
Showing 5 of 42 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 2 |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | 50.0% | 50.0% |
Organization relationships (23)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Government of the United States of America | Co sponsors trial with | 5 |
| GeneOne Life Science, Inc. | Co sponsors trial with | 4 |
| Coalition for Epidemic Preparedness Innovations | Co sponsors trial with | 2 |
| University of Pittsburgh | Co sponsors trial with | 1 |
| Vaccine Research Center | Co sponsors trial with | 1 |
Showing 5 of 23 relationships.
Latest dated events (196)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-10-30 | PDUFA decision date | Regulatory decision dates extracted from SEC filings |
| 2026-07-29 | Public offering | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-06-25 | FDA inspection | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-04-02 | Public offering | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-04-01 | At-the-market offering | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 196 events.
Biomarker capability evidence (174)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ABL1 | Trial collaborator | Named in trial inclusion criteria |
| ADPRS | Trial collaborator | Named in trial inclusion criteria |
| AFP | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
| AR | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 174 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, fda warning letters, fda untitled letters, fda recalls, fda import refusals, manufacturing and distribution sites, clia clinical laboratory certificates, and biomarkers this organization publishes on.